【佳学基因检测】有时结果不是答案：使用互补测试得出的真相和谎言

基因治疗肿瘤贼新方法简介

研讨三甲医师职称提升肿瘤学在《肿瘤致病基因检测与转移潜能分析》收录《Genetics》在. 2006 Sep;174(1):5-15.发表了一篇题目为《有时结果不是答案：使用互补测试得出的真相和谎言》肿瘤靶向药物治疗基因检测临床研究文章。该研究由R Scott Hawley, William D Gilliland等完成。促进了肿瘤的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

肿瘤靶向治疗基因检测临床应用结果

通过执行互补测试来确定两个独立获得的突变体是否定义相同或不同的基因是标准的遗传实践。虽然互补测试在大多数情况下非常有效和正确，但在许多情况下，互补测试提供了误导性的答案，要么是由于位于不同基因中的两个突变未能相互补充，要么表现出位于同一基因内的两个突变之间的互补性。基因解码基因检测在这里主要关注两个突变位于不同基因中但仍不能相互补充的情况。这种现象通常被称为第二位点非互补 (SSNC)。 SSNC 的发现导致大量筛选旨在搜索编码相互作用蛋白质的基因。然而，与基于 SSNC 的筛选相比，筛选给定基因的半显性等位基因的显性增强子突变已证明在识别相互作用基因方面更有效，这些基因的产物与感兴趣的初始基因发生物理或功能相互作用。基因解码基因检测的研究结论：Pyro- GPS 可以作为预测 BRCA 患者预后的有希望的标志。风险评分评估可能有助于获取肿瘤免疫微环境、基因组突变状态、功能通路和药物敏感性的相关信息，从而提供更有效的个性化策略。药物敏感性;基因组突变；体外实验靶向CCL5；蛋白质泛素化；焦亡;焦亡基因预后特征；肿瘤免疫微环境。

肿瘤发生与反复转移国际数据库描述：

It is standard genetic practice to determine whether or not two independently obtained mutants define the same or different genes by performing the complementation test. While the complementation test is highly effective and accurate in most cases, there are a number of instances in which the complementation test provides misleading answers, either as a result of the failure of two mutations that are located in different genes to complement each other or by exhibiting complementation between two mutations that lie within the same gene. We are primarily concerned here with those cases in which two mutations lie in different genes, but nonetheless fail to complement each other. This phenomenon is often referred to as second-site noncomplementation (SSNC). The discovery of SSNC led to a large number of screens designed to search for genes that encode interacting proteins. However, screens for dominant enhancer mutations of semidominant alleles of a given gene have proved far more effective at identifying interacting genes whose products interact physically or functionally with the initial gene of interest than have SSNC-based screens.Conclusions: The risk score of Pyro-GPS can serve as a promising hallmark to predict the prognosis of BRCA patients. Risk score evaluation may assist to acquire relevant information of tumor immune microenvironment, genomic mutation status, functional pathways and drug sensitivity, and thus provide more effective personalized strategies.Keywords: breast cancer; drug sensitivity; genomic mutation; in vitro experiment targeted CCL5; protein ubiquitination; pyroptosis; pyroptotic gene prognostic signatures; tumor immune microenvironment.